Scott Turicchi: Yes, that’s something we’d like to be able to know as well. As I mentioned in my opening remarks, although I gave some directional guidance for next year, it’s clearly not the formal guidance nor is it a budget. As John noted in his comments, we had a very substantive meeting back in late August with not only Cognosante the VA and their various representatives. Here we sit in almost mid-November and there still is a plan being worked through in terms of exactly how the rollout will proceed. And if I had to put it into two buckets the initial phase that we discussed last quarter that concluded with the 40 sites was done on a site basis and the philosophy was that you would take each individual unit call it a clinic hospital et cetera and you would convert everything within that facility from what they were currently doing to ECFax.
ow that’s not the way we would generally roll out a large-scale corporate enterprise. What has occurred in this sort of next phase that we have been rolling out is and John noted this is we are rolling out more facilities but not necessarily taking all the pieces at a moment in time. And this is an important distinction because there are layers of methods by which fax can be sent and received within an organization. To give you some idea, they’re individual numbers, point-to-point communications, there’s fax that travels inbound versus outbound. Some maybe on servers; some maybe associated with multifunction devices, of which there could be a variety think HP Ricoh, Canon, Lexmark Brother, et cetera. There are applications where you can fax the application or it can be received in.
So it’s a non-trivial exercise to think about taking an organization or an office and converting everything they do because likely they use all of these formats and converting them all. So typically what we would do is we would go in order. And the order would be generally how you can get the most users on a platform quickly and also where there is the most concentration of traffic. And I think as John noted in his remarks there is an alignment here between the VA’s objectives, Cognosante’s objectives and our objectives which is more usage more users even if it’s not necessarily a complete facility that transitions over at a moment in time. Having said that, we’re still working through with Cognosante and the VA what that exactly means and what a rollout going forward looks like.
So it’s a lengthy answer to let you know that it’s very much of a work in progress. What we can say is that there’s very little revenue in 2023 what we book to-date and we’re more likely to book in the remaining 50 days 60 days of the year. So we do believe there will be a substantial uptick off a very small base in 2023. But even amongst ourselves, there’s some range of what that number could be. My own belief and view is it should be seven digits but where it is in the seven-digit range is very much a question I think yet to be answered. And obviously we will refine that number. And when we release our 2024 guidance in conjunction with the Q4 call, we’ll have a more explicit I think view on that.
Pete Lukas: Very helpful. Thanks. I’ll jump back in the queue.
Operator: Okay. [Operator Instructions] The next question is coming from Fatima Boolani from Citi. Fatima, your line is live.
Q –Unidentified Analyst: Hey. Good afternoon, guys. This is Mark on for Fatima. Thanks for taking our questions. Maybe one for Johnny. I understand it’s still early days – early in the process before you get into the CRO role. But when you take on the CRO role any sort of early points you can share on your plans there? Should we maybe expect changes in sales incentives or go-to-market initiatives? And then any sort of color around areas of upside or downside risk as you’re going to 2024 aside from the obvious macro headwinds? Thanks.
